DRTS

Alpha Tau Medical Ltd.

A maker of a novel cancer treatment called Alpha DaRT, Alpha Tau Medical places tiny radioactive seeds directly inside solid tumors to deliver a concentrated burst of alpha radiation that destroys cancer cells while sparing nearby healthy tissue. The Israeli company, founded in Jerusalem, grew out of academic research and is named for the alpha particles at the heart of its therapy. Alpha DaRT is now being studied around the world as a potential option for skin, head-and-neck, and pancreatic cancers.

CINS: M0740A108ISIN: IL0011839383HealthcareIL3 holders

Ownership Activity Financials Filings

Schedule 13D / 13G filings

Uzi Sofer

13GPassive

% of class15.8%

Shares13.70M

FiledJul 24, 2025

Oramed Pharmaceuticals Inc.

13DActivist

% of class19.99%

Shares14.11M

FiledMay 1, 2025

Share Purchase Agreement On April 24, 2025, Oramed Ltd. entered into a Share Purchase Agreement (the "Purchase Agreement") with the Issuer for the purchase by Oramed Ltd. of 14,110,121 Ordinary Shares of the Issuer, in a registered direct offering (the "Offering"), at a purchase price of $2.612 per share. The aggregate purchase price paid for the Ordinary Shares of the Issuer was approximately $36.9 million, prior to the Issuer's deduction of estimated offering expenses payable by the Issuer. The closing of the Offering occurred on April 28, 2025 (the "Closing Date"). The Purchase Agreement contains customary representations, warranties and agreements by the Issuer and Oramed Ltd., customary conditions to closing, indemnification obligations of the Issuer, other obligations of the parties, and termination provisions. Additionally, pursuant to the terms of the Purchase Agreement, on or before the three month anniversary of the Closing Date, Oramed Ltd. shall have the right to nominate two persons to serve as directors on the Issuer's board of directors (the "Board of Directors"), subject to certain customary conditions, and the Issuer has agreed it shall not increase the size of its Board of Directors above eight members without the prior written consent of the Purchaser, until such time as (i) Oramed Ltd. owns less than 10% of the outstanding shares of the Issuer or (ii) is not the largest shareholder of the Issuer. Strategic Services Agreement On April 24, 2025, concurrent with the execution of the Purchase Agreement, Oramed Ltd. entered into a Strategic IR/PR Services Agreement (the "Strategic Services Agreement") with the Issuer, whereby the Issuer engaged Oramed Ltd., on a non-exclusive basis, to provide the Issuer with comprehensive strategic investor relations and public relations management services in certain territories including the United States, Israel and South Korea. As consideration for the services to be provided pursuant to the Strategic Services Agreement, the Issuer has agreed to pay Oramed Ltd. an aggregate non-refundable fee of $3,000,000, with $500,000 payable upon execution of the Strategic Services Agreement and the remaining $2,500,000 payable in five equal instalments every six months following the date of the Strategic Services Agreement. In addition, subject to the approval by the Issuer's shareholders at its upcoming Annual General Meeting, the Issuer agreed to issue to Oramed Ltd. (i) warrants to purchase up to 2,390,000 Ordinary Shares at an exercise price $3.90 per share and (ii) warrants to purchase up to 847,000 Ordinary Shares at an exercise price of $3.474 per share (collectively, the "IR/PR Warrants"). The IR/PR Warrants will be issued as restricted securities, will be exercisable immediately upon issuance, and will expire on the 2.5 year anniversary of the effective date of the Strategic Services Agreement. The Issuer has agreed to register the Ordinary Shares issuable upon exercise of the IR/PR Warrants for resale by Oramed Ltd. within sixty days of the effective date of the Strategic Services Agreement and to have such resale registration statement declared effective within ninety days of the date of the Strategic Services Agreement (or in the event of a "full review" by the SEC, 120 days following the date of the Strategic Services Agreement). The term of the Strategic Services Agreement is for three years and neither Oramed Ltd. nor the Issuer may terminate the Strategic Services Agreement prior to the end of the term, except in the event of a material breach (not cured within ten calendar days from the date the breaching party became aware of such breach) or if the other party has been accused of any crime or impropriety which pertains to activities which are similar in nature to the services to be provided under the Strategic Services Agreement. The foregoing descriptions of the Purchase Agreement and the Strategic Services Agreement do not purport to be complete and are qualified in their entirety by reference to forms of the Purchase Agreement and the Strategic Services Agreement, which are incorporated herein by reference to Exhibits 99.2 and 99.3 of this Schedule 13D, respectively. General The Reporting Persons intend to review their investment in the Issuer on a continuing basis taking into consideration various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Ordinary Shares of the Issuer, in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time, which may include further acquisitions of the Ordinary Shares of the Issuer or disposal of some or all of the Ordinary Shares of the Issuer owned by the Reporting Persons or otherwise acquired by the Reporting Persons, either in the open market or in privately negotiated transactions. Any open market or privately negotiated purchases or sales, acquisition recommendations or proposals or other transactions concerning the Issuer may be made at any time without prior notice. Any alternative may depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities, the financial condition, results of operations and prospects of the Issuer and general industry conditions, the availability, form and terms of financing, other investment and business opportunities, general stock market and economic conditions, tax considerations and other factors. Although the foregoing reflects plans and proposals presently contemplated by each Reporting Person with respect to the Issuer, the foregoing is subject to change at any time and dependent upon contingencies and assumed and speculative conditions, and there can be no assurance that any of the actions set forth above will be taken. The Reporting Persons have in the past, and may in the future, engage in discussions with the Issuer's management, board of directors, and/or other shareholders covering a broad range of subjects, including relative to performance, strategic direction, capital allocation, shareholder value, board composition and governance of the Issuer. Depending upon each factor discussed above and any other factor (which may be unknown at this time) that is, or may become relevant, the Reporting Persons may consider, among other things: (a) the acquisition by the Reporting Persons of additional securities of the Issuer, the disposition of securities of the Issuer, or the exercise of convertible securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to those enumerated above. Except to the extent that the foregoing may be deemed to be a plan or proposal, neither of the Reporting Persons currently have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of Item 4 of Schedule 13D. Depending upon the foregoing factors and to the extent deemed advisable in light of their general investment policies, or other factors, the Reporting Persons may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Issuer or the Ordinary Shares of the Issuer, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The foregoing is subject to change at any time, and there can be no assurance that any of the Reporting Persons will take any of the actions set forth above.

Oramed Ltd.

13DActivist

% of class19.99%

Shares14.11M

FiledMay 1, 2025

Holder	Schedule	% of class	Shares	Filed
Uzi Sofer	13GPassive	15.8%	13.70M	Jul 24, 2025
Oramed Pharmaceuticals Inc.	13DActivist	19.99%	14.11M	May 1, 2025
Share Purchase Agreement On April 24, 2025, Oramed Ltd. entered into a Share Purchase Agreement (the "Purchase Agreement") with the Issuer for the purchase by Oramed Ltd. of 14,110,121 Ordinary Shares of the Issuer, in a registered direct offering (the "Offering"), at a purchase price of $2.612 per share. The aggregate purchase price paid for the Ordinary Shares of the Issuer was approximately $36.9 million, prior to the Issuer's deduction of estimated offering expenses payable by the Issuer. The closing of the Offering occurred on April 28, 2025 (the "Closing Date"). The Purchase Agreement contains customary representations, warranties and agreements by the Issuer and Oramed Ltd., customary conditions to closing, indemnification obligations of the Issuer, other obligations of the parties, and termination provisions. Additionally, pursuant to the terms of the Purchase Agreement, on or before the three month anniversary of the Closing Date, Oramed Ltd. shall have the right to nominate two persons to serve as directors on the Issuer's board of directors (the "Board of Directors"), subject to certain customary conditions, and the Issuer has agreed it shall not increase the size of its Board of Directors above eight members without the prior written consent of the Purchaser, until such time as (i) Oramed Ltd. owns less than 10% of the outstanding shares of the Issuer or (ii) is not the largest shareholder of the Issuer. Strategic Services Agreement On April 24, 2025, concurrent with the execution of the Purchase Agreement, Oramed Ltd. entered into a Strategic IR/PR Services Agreement (the "Strategic Services Agreement") with the Issuer, whereby the Issuer engaged Oramed Ltd., on a non-exclusive basis, to provide the Issuer with comprehensive strategic investor relations and public relations management services in certain territories including the United States, Israel and South Korea. As consideration for the services to be provided pursuant to the Strategic Services Agreement, the Issuer has agreed to pay Oramed Ltd. an aggregate non-refundable fee of $3,000,000, with $500,000 payable upon execution of the Strategic Services Agreement and the remaining $2,500,000 payable in five equal instalments every six months following the date of the Strategic Services Agreement. In addition, subject to the approval by the Issuer's shareholders at its upcoming Annual General Meeting, the Issuer agreed to issue to Oramed Ltd. (i) warrants to purchase up to 2,390,000 Ordinary Shares at an exercise price $3.90 per share and (ii) warrants to purchase up to 847,000 Ordinary Shares at an exercise price of $3.474 per share (collectively, the "IR/PR Warrants"). The IR/PR Warrants will be issued as restricted securities, will be exercisable immediately upon issuance, and will expire on the 2.5 year anniversary of the effective date of the Strategic Services Agreement. The Issuer has agreed to register the Ordinary Shares issuable upon exercise of the IR/PR Warrants for resale by Oramed Ltd. within sixty days of the effective date of the Strategic Services Agreement and to have such resale registration statement declared effective within ninety days of the date of the Strategic Services Agreement (or in the event of a "full review" by the SEC, 120 days following the date of the Strategic Services Agreement). The term of the Strategic Services Agreement is for three years and neither Oramed Ltd. nor the Issuer may terminate the Strategic Services Agreement prior to the end of the term, except in the event of a material breach (not cured within ten calendar days from the date the breaching party became aware of such breach) or if the other party has been accused of any crime or impropriety which pertains to activities which are similar in nature to the services to be provided under the Strategic Services Agreement. The foregoing descriptions of the Purchase Agreement and the Strategic Services Agreement do not purport to be complete and are qualified in their entirety by reference to forms of the Purchase Agreement and the Strategic Services Agreement, which are incorporated herein by reference to Exhibits 99.2 and 99.3 of this Schedule 13D, respectively. General The Reporting Persons intend to review their investment in the Issuer on a continuing basis taking into consideration various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Ordinary Shares of the Issuer, in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time, which may include further acquisitions of the Ordinary Shares of the Issuer or disposal of some or all of the Ordinary Shares of the Issuer owned by the Reporting Persons or otherwise acquired by the Reporting Persons, either in the open market or in privately negotiated transactions. Any open market or privately negotiated purchases or sales, acquisition recommendations or proposals or other transactions concerning the Issuer may be made at any time without prior notice. Any alternative may depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities, the financial condition, results of operations and prospects of the Issuer and general industry conditions, the availability, form and terms of financing, other investment and business opportunities, general stock market and economic conditions, tax considerations and other factors. Although the foregoing reflects plans and proposals presently contemplated by each Reporting Person with respect to the Issuer, the foregoing is subject to change at any time and dependent upon contingencies and assumed and speculative conditions, and there can be no assurance that any of the actions set forth above will be taken. The Reporting Persons have in the past, and may in the future, engage in discussions with the Issuer's management, board of directors, and/or other shareholders covering a broad range of subjects, including relative to performance, strategic direction, capital allocation, shareholder value, board composition and governance of the Issuer. Depending upon each factor discussed above and any other factor (which may be unknown at this time) that is, or may become relevant, the Reporting Persons may consider, among other things: (a) the acquisition by the Reporting Persons of additional securities of the Issuer, the disposition of securities of the Issuer, or the exercise of convertible securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to those enumerated above. Except to the extent that the foregoing may be deemed to be a plan or proposal, neither of the Reporting Persons currently have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of Item 4 of Schedule 13D. Depending upon the foregoing factors and to the extent deemed advisable in light of their general investment policies, or other factors, the Reporting Persons may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Issuer or the Ordinary Shares of the Issuer, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The foregoing is subject to change at any time, and there can be no assurance that any of the Reporting Persons will take any of the actions set forth above.
Oramed Ltd.	13DActivist	19.99%	14.11M	May 1, 2025
Share Purchase Agreement On April 24, 2025, Oramed Ltd. entered into a Share Purchase Agreement (the "Purchase Agreement") with the Issuer for the purchase by Oramed Ltd. of 14,110,121 Ordinary Shares of the Issuer, in a registered direct offering (the "Offering"), at a purchase price of $2.612 per share. The aggregate purchase price paid for the Ordinary Shares of the Issuer was approximately $36.9 million, prior to the Issuer's deduction of estimated offering expenses payable by the Issuer. The closing of the Offering occurred on April 28, 2025 (the "Closing Date"). The Purchase Agreement contains customary representations, warranties and agreements by the Issuer and Oramed Ltd., customary conditions to closing, indemnification obligations of the Issuer, other obligations of the parties, and termination provisions. Additionally, pursuant to the terms of the Purchase Agreement, on or before the three month anniversary of the Closing Date, Oramed Ltd. shall have the right to nominate two persons to serve as directors on the Issuer's board of directors (the "Board of Directors"), subject to certain customary conditions, and the Issuer has agreed it shall not increase the size of its Board of Directors above eight members without the prior written consent of the Purchaser, until such time as (i) Oramed Ltd. owns less than 10% of the outstanding shares of the Issuer or (ii) is not the largest shareholder of the Issuer. Strategic Services Agreement On April 24, 2025, concurrent with the execution of the Purchase Agreement, Oramed Ltd. entered into a Strategic IR/PR Services Agreement (the "Strategic Services Agreement") with the Issuer, whereby the Issuer engaged Oramed Ltd., on a non-exclusive basis, to provide the Issuer with comprehensive strategic investor relations and public relations management services in certain territories including the United States, Israel and South Korea. As consideration for the services to be provided pursuant to the Strategic Services Agreement, the Issuer has agreed to pay Oramed Ltd. an aggregate non-refundable fee of $3,000,000, with $500,000 payable upon execution of the Strategic Services Agreement and the remaining $2,500,000 payable in five equal instalments every six months following the date of the Strategic Services Agreement. In addition, subject to the approval by the Issuer's shareholders at its upcoming Annual General Meeting, the Issuer agreed to issue to Oramed Ltd. (i) warrants to purchase up to 2,390,000 Ordinary Shares at an exercise price $3.90 per share and (ii) warrants to purchase up to 847,000 Ordinary Shares at an exercise price of $3.474 per share (collectively, the "IR/PR Warrants"). The IR/PR Warrants will be issued as restricted securities, will be exercisable immediately upon issuance, and will expire on the 2.5 year anniversary of the effective date of the Strategic Services Agreement. The Issuer has agreed to register the Ordinary Shares issuable upon exercise of the IR/PR Warrants for resale by Oramed Ltd. within sixty days of the effective date of the Strategic Services Agreement and to have such resale registration statement declared effective within ninety days of the date of the Strategic Services Agreement (or in the event of a "full review" by the SEC, 120 days following the date of the Strategic Services Agreement). The term of the Strategic Services Agreement is for three years and neither Oramed Ltd. nor the Issuer may terminate the Strategic Services Agreement prior to the end of the term, except in the event of a material breach (not cured within ten calendar days from the date the breaching party became aware of such breach) or if the other party has been accused of any crime or impropriety which pertains to activities which are similar in nature to the services to be provided under the Strategic Services Agreement. The foregoing descriptions of the Purchase Agreement and the Strategic Services Agreement do not purport to be complete and are qualified in their entirety by reference to forms of the Purchase Agreement and the Strategic Services Agreement, which are incorporated herein by reference to Exhibits 99.2 and 99.3 of this Schedule 13D, respectively. General The Reporting Persons intend to review their investment in the Issuer on a continuing basis taking into consideration various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Ordinary Shares of the Issuer, in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time, which may include further acquisitions of the Ordinary Shares of the Issuer or disposal of some or all of the Ordinary Shares of the Issuer owned by the Reporting Persons or otherwise acquired by the Reporting Persons, either in the open market or in privately negotiated transactions. Any open market or privately negotiated purchases or sales, acquisition recommendations or proposals or other transactions concerning the Issuer may be made at any time without prior notice. Any alternative may depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities, the financial condition, results of operations and prospects of the Issuer and general industry conditions, the availability, form and terms of financing, other investment and business opportunities, general stock market and economic conditions, tax considerations and other factors. Although the foregoing reflects plans and proposals presently contemplated by each Reporting Person with respect to the Issuer, the foregoing is subject to change at any time and dependent upon contingencies and assumed and speculative conditions, and there can be no assurance that any of the actions set forth above will be taken. The Reporting Persons have in the past, and may in the future, engage in discussions with the Issuer's management, board of directors, and/or other shareholders covering a broad range of subjects, including relative to performance, strategic direction, capital allocation, shareholder value, board composition and governance of the Issuer. Depending upon each factor discussed above and any other factor (which may be unknown at this time) that is, or may become relevant, the Reporting Persons may consider, among other things: (a) the acquisition by the Reporting Persons of additional securities of the Issuer, the disposition of securities of the Issuer, or the exercise of convertible securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to those enumerated above. Except to the extent that the foregoing may be deemed to be a plan or proposal, neither of the Reporting Persons currently have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of Item 4 of Schedule 13D. Depending upon the foregoing factors and to the extent deemed advisable in light of their general investment policies, or other factors, the Reporting Persons may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Issuer or the Ordinary Shares of the Issuer, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The foregoing is subject to change at any time, and there can be no assurance that any of the Reporting Persons will take any of the actions set forth above.